Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
146 Leser
Artikel bewerten:
(0)

Elekta Cancer Treatment Solutions to Have Significant Impact on Patients at Cork University Hospital

CRAWLEY, United Kingdom, May 25, 2018 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that Cork University Hospital has ordered five Elekta Versa HD linear accelerators, as well as Elekta's Monaco treatment planning system, MOSAIQ oncology information system, and brachytherapy equipment, providing an integrated solution for advanced cancer treatment.

Versa HD is designed to improve cancer patient care by combining high definition dynamic radiosurgery treatments and precision radiotherapy in a single platform. Versa HD provides the flexibility to treat a broad spectrum of tumors throughout the body, while enabling treatment of highly complex cancers that require extreme targeting precision.

Dr. Paul Kelly, Radiation Oncologist at Cork University Hospital, said: "The new Elekta equipment will help us achieve optimal outcomes for our cancer patients by consistently applying best practices in patient care and treatment. The hardware and software together offer Cork University Hospital a solution that provides the flexibility to meet ongoing changing requirements in areas that include service design, increasing demand, clinical and technological innovation."

Steve Tomkins, Elekta's Business Unit Manager for UK, Ireland and Nordics added: "According to the Irish Cancer Society, an average of 40,000 new cases of cancer are diagnosed each year in the country. However, more than 165,000 people are living with cancer as a chronic disease thanks to treatments such as radiation therapy. Elekta is honored to play a significant role in improving and saving the lives of cancer patients in Ireland and in Cork particularly."

The equipment was acquired through Ireland's National Plan for Radiation Oncology (NPRO), and will replace the existing installed base of competing systems. All solutions were booked in the fourth quarter of Elekta's 2017/18 fiscal year and first deliveries are scheduled for early 2019.

For further information, please contact:

Oskar Bosson
Global EVP Corporate Communications and Investor Relations
Tel: +46-70-410-7180
e-mail: Oskar.Bosson@elekta.com
Time zone: CET: Central European Time

Michelle Joiner
Director, Global Media Relations
Tel: +1-770-670-2447
e-mail: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

About Elekta

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/elekta/r/elekta-cancer-treatment-solutions-to-have-significant-impact-on-patients-at-cork-university-hospital,c2531140

The following files are available for download:

http://mb.cision.com/Main/35/2531140/848069.pdf

PDF

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2018 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.